Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Innate Pharma SA ( (FR:IPH) ) just unveiled an announcement.
Innate Pharma S.A. announced that four of its clinical development abstracts have been accepted for presentation at the ASCO 2025 Annual Meeting, scheduled for May 30 to June 3 in Chicago. The company will present long-term follow-up results from the TELLOMAK Phase 2 trial in Sézary syndrome and mycosis fungoides, as well as a trial in progress poster on IPH4502 for advanced solid tumors. AstraZeneca will also present updated results from the NeoCOAST-2 Phase 2 trial in resectable NSCLC. This participation underscores Innate Pharma’s commitment to advancing innovative cancer therapies and may enhance its industry positioning by showcasing its research progress to a global audience.
The most recent analyst rating on (FR:IPH) stock is a Buy with a EUR5.70 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs) to treat various tumor types. Innate Pharma collaborates with major biopharmaceutical companies like Sanofi and AstraZeneca and is headquartered in Marseille, France, with a US office in Rockville, MD.
YTD Price Performance: -0.78%
Average Trading Volume: 135,485
Technical Sentiment Signal: Sell
Current Market Cap: €176.6M
See more insights into IPH stock on TipRanks’ Stock Analysis page.